Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer

Journal of Surgical Oncology

Volumn 108, Issue 4, 2013, Pages 236-241

  Boone, Brian A ^a   Steve, Jennifer ^a   Krasinskas, Alyssa M ^b   Zureikat, Amer H ^a   Lembersky, Barry C ^c   Gibson, Michael K ^c   Stoller, Ronald G ^c   Zeh, Herbert J ^a   Bahary, Nathan ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

borderline resectable; locally unresectable; neoadjuvant treatment; pancreatic cancer: FOLFIRINOX

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLURRED VISION; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; SIDE EFFECT; SPLEEN VEIN THROMBOSIS; STEREOTACTIC BODY RADIATION THERAPY; THROMBOCYTOPENIA; UNRESECTABLE PANCREATIC CANCER; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION;

BORDERLINE RESECTABLE; LOCALLY UNRESECTABLE; NEOADJUVANT TREATMENT; PANCREATIC CANCER: FOLFIRINOX;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RADIOSURGERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84882402665     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23392     Document Type: Article

References (50)

1. Eheman C, Henley SJ, Ballard-Barbash R, et al.: Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012; 118: 2338-2366.
2. Geer RJ, Brennan MF:, Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68-72. discussion 72-63.
3. Landry J, Catalano PJ, Staley C, et al.: Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010; 101: 587-592.
4. Truty MJ, Thomas RM, Katz MH, et al.: Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 2012; 215: 41-51. discussion 51-42.
5. Katz MH, Pisters PW, Evans DB, et al.: Borderline resectable pancreatic cancer: The importance of this emerging stage of disease. J Am Coll Surg 2008; 206: 833-846. discussion 846-838.
6. Varadhachary GR, Tamm EP, Abbruzzese JL, et al.: Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
7. Habermehl D, Kessel K, Welzel T, et al.: Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol 2012; 7: 28.
8. Arvold ND, Ryan DP, Niemierko A, et al.: Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012; 118: 3026-3035.
9. Barugola G, Partelli S, Crippa S, et al.: Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012; 203: 132-139.
10. Lee JL, Kim SC, Kim JH, et al.: Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012; 152: 851-862.
11. Leone F, Gatti M, Massucco P, et al.: Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. Cancer 2012; 119: 277-284.
12. Marti JL, Hochster HS, Hiotis SP, et al.: Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008; 15: 3521-3531.
13. Pipas JM, Zaki BI, McGowan MM, et al.: Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol 2012; 23: 2820-2827.
14. Sahora K, Kuehrer I, Eisenhut A, et al.: NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011; 149: 311-320.
15. Sahora K, Kuehrer I, Schindl M, et al.: NeoGemTax: Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 2011; 35: 1580-1589.
16. Turrini O, Viret F, Moureau-Zabotto L, et al.: Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol 2009; 35: 1306-1311.
17. Milandri C, Polico R, Garcea D, et al.: GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. Hepatogastroenterology 2011; 58: 599-603.
18. Polistina F, Costantin G, Casamassima F, et al.: Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010; 17: 2092-2101.
19. Strobel O, Berens V, Hinz U, et al.: Resection after neoadjuvant therapy for locally advanced, "unresectable" pancreatic cancer. Surgery 2012; 152: S33-S42.
20. Brunner TB:, Neoadjuvant therapy for potentially resectable pancreatic cancer: An emerging paradigm ? Curr Oncol Rep 2013; 15: 162-169.
21. Goff SL, Chabot JA:, A neoadjuvant strategy for the management of nonmetastatic pancreatic cancer. Cancer J 2012; 18: 602-608.
22. Wolff RA:, Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas. Curr Drug Targets 2012; 13: 781-788.
23. Lal A, Christians K, Evans DB:, Management of borderline resectable pancreatic cancer. Surg Oncol Clin N Am 2010; 19: 359-370.
24. Andriulli A, Festa V, Botteri E, et al.: Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: A meta-analysis of prospective studies. Ann Surg Oncol 2012; 19: 1644-1662.
25. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
26. Ychou M, Conroy T, Seitz JF, et al.: An open phase I study assessing the feasibility of the triple combination: Oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003; 14: 481-489.
27. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al.: 5-fluorouracil/ leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80: 301-306.
28. Conroy T, Paillot B, Francois E, et al.: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23: 1228-1236.
29. Peddi PF, Lubner S, McWilliams R, et al.: Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13: 497-501.
30. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al.: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31: 23-29.
31. Callery MP, Chang KJ, Fishman EK, et al.: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
32. Verbeke CS, Leitch D, Menon KV, et al.: Redefining the R1 resection in pancreatic cancer. Br J Surg 2006; 93: 1232-1237.
33. Compton CC, Henson DE:, Protocol for the examination of specimens removed from patients with carcinoma of the exocrine pancreas: A basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med 1997; 121: 1129-1136.
34. Clavien PA, Barkun J, de Oliveira ML, et al.: The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009; 250: 187-196.
35. Bassi C, Dervenis C, Butturini G, et al.: Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 2005; 138: 8-13.
36. Malik NK, May KS, Chandrasekhar R, et al.: Treatment of locally advanced unresectable pancreatic cancer: A 10-year experience. J Gastrointest Oncol 2012; 3: 326-334.
37. Evans DB, Rich TA, Byrd DR, et al.: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
38. Yachida S, Jones S, Bozic I, et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
39. Rhim AD, Mirek ET, Aiello NM, et al.: EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-361.
40. Haeno H, Gonen M, Davis MB, et al.: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375.
41. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al.: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.
42. Assifi MM, Lu X, Eibl G, et al.: Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials. Surgery 2011; 150: 466-473.
43. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10-15.
44. Katz A, Hanlon A, Lanciano R, et al.: Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41: 393-396.
45. Nakai Y, Kawabe T, Isayama H, et al.: CA 19-19 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008; 75: 120-126.
46. Reni M, Cereda S, Balzano G, et al.: Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115: 2630-2639.
47. Hosein PJ, Macintyre J, Kawamura C, et al.: A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12: 199.
48. Chatterjee D, Katz MH, Rashid A, et al.: Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer 2012; 118: 3182-3190.
49. Zhao Q, Rashid A, Gong Y, et al.: Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol 2012; 16: 29-37.
50. Katz MH, Marsh R, Herman JM, et al.: Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-2795.